BioSpace News Archive

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), announces that Transcenta has presented the safety/tolerability and preliminary anti-tumor activity data in gastric and pancreatic cancers of TST001 China phase I clinical trial as a poster presentation at the 2022 International Gastric Cancer Congress (IGCC).

Faron Pharmaceuticals Ltd announces that an analysis of biomarker data from patients treated with bexmarilimab as part of the ongoing phase I/II MATINS trial, will be presented at the upcoming American Association for Cancer Research Annual Meeting being held in New Orleans, US, from April 8 - 13, 2022.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum taking place virtually on March 23, 2022.

Seneca Therapeutics, Inc. announced the publication of an abstract “Oncolytic Seneca Valley Virus overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model” at the upcoming American Association for Cancer Research meeting in New Orleans, LA.

Design Therapeutics, Inc. today announced that preclinical data supporting the potential of the company’s novel GeneTAC™ small molecules to correct the most common underlying genetic cause of Fuchs endothelial corneal dystrophy (FECD) will be presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting (ARVO 2022).

TYME Technologies, Inc. today announced the availability of the poster abstract, “SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor positive breast cancer,” which was submitted by researchers from Georgetown University.

Pfizer Inc. (NYSE: PFE) announced today that it has initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients), to evaluate the safety, pharmacokinetics, and efficacy of Pfizer’s PAXLOVID.

Medicenna Therapeutics Corp. announced the publication of two abstracts that have been accepted for electronic poster presentations at the American Association for Cancer Research Annual Meeting, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans, Louisiana from April 8-13, 2022.

Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, provides a business update and unaudited financial results for Q4 2021 and the full year ended December 31, 2021.

AIM ImmunoTech Inc. announced that oncology experts from Roswell Park Comprehensive Cancer Center will present findings from two ongoing clinical studies involving an AIM ImmunoTech Inc. drug candidate, Ampligen® at the American Association for Cancer Research Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.